Moreover, genetically reducing Nrp1 levels enhances the severity of CMT2D pathology, whereas providing additional VEGF-A165, via lentiviral intramuscular injections, improves the phenotype10. The gene discussed is NRP1; the disease is Charcot-Marie-Tooth disease type 2D.